GSK To Address Multiple Myeloma With First-In-Class Blenrep In EU
Approval Conditional On Further Studies, Risk Management Plan
The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.
You may also be interested in...
The UK-headquartered company is in transition, investing heavily in biopharma R&D and preparing to spin out its consumer division.
If bad luck comes in threes, GSK will be delighted to see the end of this week with dostarlimab approval delayed, bintrafusp failing in lung cancer and a Phase II of an ulcerative colitis drug discontinued.
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.